Public Sector Pension Investment Board Has $3.89 Million Stock Holdings in NeoGenomics, Inc. $NEO

Public Sector Pension Investment Board raised its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 14.8% in the 3rd quarter, HoldingsChannel reports. The firm owned 503,860 shares of the medical research company’s stock after acquiring an additional 65,098 shares during the quarter. Public Sector Pension Investment Board’s holdings in NeoGenomics were worth $3,890,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Moody National Bank Trust Division increased its position in NeoGenomics by 1.4% in the 3rd quarter. Moody National Bank Trust Division now owns 90,476 shares of the medical research company’s stock valued at $698,000 after buying an additional 1,227 shares in the last quarter. Amalgamated Bank grew its stake in NeoGenomics by 3.4% in the third quarter. Amalgamated Bank now owns 37,965 shares of the medical research company’s stock valued at $293,000 after acquiring an additional 1,255 shares during the period. Moors & Cabot Inc. increased its holdings in shares of NeoGenomics by 20.0% during the second quarter. Moors & Cabot Inc. now owns 12,000 shares of the medical research company’s stock valued at $88,000 after acquiring an additional 2,000 shares in the last quarter. State of Tennessee Department of Treasury raised its position in shares of NeoGenomics by 3.6% during the second quarter. State of Tennessee Department of Treasury now owns 58,082 shares of the medical research company’s stock worth $425,000 after purchasing an additional 2,039 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of NeoGenomics by 3.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 65,004 shares of the medical research company’s stock worth $475,000 after purchasing an additional 2,238 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on NEO. TD Cowen restated a “buy” rating on shares of NeoGenomics in a research note on Wednesday, January 7th. Leerink Partners set a $14.00 target price on shares of NeoGenomics in a research report on Tuesday, October 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday, December 29th. Benchmark reissued a “hold” rating on shares of NeoGenomics in a report on Wednesday. Finally, Zacks Research raised NeoGenomics from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $11.57.

NeoGenomics Stock Down 1.2%

NeoGenomics stock opened at $9.89 on Friday. NeoGenomics, Inc. has a fifty-two week low of $4.72 and a fifty-two week high of $13.74. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.62 and a current ratio of 4.26. The firm’s 50-day simple moving average is $12.06 and its 200 day simple moving average is $10.14. The stock has a market cap of $1.28 billion, a PE ratio of -11.77 and a beta of 1.58.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, February 17th. The medical research company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. NeoGenomics had a negative net margin of 14.85% and a negative return on equity of 3.10%. The firm had revenue of $190.17 million during the quarter, compared to analyst estimates of $188.25 million. During the same quarter last year, the business posted $0.04 EPS. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. Research analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Alicia C. Olivo sold 20,916 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total transaction of $250,992.00. Following the completion of the sale, the executive vice president directly owned 31,083 shares of the company’s stock, valued at $372,996. This trade represents a 40.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Warren Stone sold 22,128 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total transaction of $276,600.00. Following the completion of the transaction, the chief operating officer directly owned 121,631 shares in the company, valued at $1,520,387.50. This trade represents a 15.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 2.40% of the company’s stock.

NeoGenomics Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.